[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589251":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":21,"studyPopulation":22,"armGroups":23,"interventions":29,"overallOfficials":17,"centralContacts":34,"locations":44,"responsibleParty":61,"collaborators":65,"id":67,"slug":17,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":17,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":80,"studyType":81,"phases":17,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":47,"whyStopped":17,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Standardized uptake value (SUV)","Standardized uptake value (SUV) of 11C\u002F18F-HED for each target lesion of subject or suspected primary tumor or\u002Fand metastasis.","30 days",[14],{"measure":15,"description":16,"timeFrame":12},"Diagnostic efficacy","The sensitivity, specificity and accuracy of HED PET\u002FCT were calculated.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Subjects with various sympathetic nerves-related disease patients underwent 11C\u002F18F-HED PET\u002FCT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 11C\u002F18F-HED PET\u002FCT were calculated.","(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.",[24],{"label":25,"type":17,"description":26,"interventionNames":27},"Single Group Assignment","Each subject receive a single intravenous injection of 11C\u002F18F-HED and undergo PET\u002FCT or MRI imaging within the specificed time.",[28],"Diagnostic Test: 11C\u002F18F-HED",[30],{"type":31,"name":32,"description":26,"armGroupLabels":33,"otherNames":17},"DIAGNOSTIC_TEST","11C\u002F18F-HED",[25],[35,40],{"name":36,"role":37,"phone":38,"phoneExt":17,"email":39},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",{"name":41,"role":37,"phone":42,"phoneExt":17,"email":43},"Qiusong Chen, MD","+862260362190","qs_c8@hotmail.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China","CN",{"type":54,"coordinates":55},"Point",[56,57],117.17667,39.14222,{"lat":57,"lon":56},[60],{"name":36,"role":37,"phone":38,"phoneExt":17,"email":39},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[66],{"name":46,"class":6},"100589251",false,"NCT06951984","Hydroxyephedrine PET\u002FCT in Sympathetic Nervous System Disease","Hydroxyephedrine PET\u002FCT in Sympathetic Nervous System Diseases","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":78,"type":79},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 11C\u002F18F-HED positron emission tomography\u002F computed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[84,85,86],"Sympathetic Nervous System Diseases","Sympathetic Nervous Structure Injury","Sympathetic Nerve Injury",[88,89,90],"PET\u002FCT","MRI","Hydroxyephedrine","2025-04-23",{"date":93,"type":94},"2025-04-30","ACTUAL",{"date":96,"type":94},"2013-03-01",{"date":98,"type":79},"2028-03-01",{"name":5,"class":6},1]